This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BOWERS, C. Y. Articles by CHANG, K. Search for Related Content PubMed PubMed Citation Articles by BOWERS, C. Y. Articles by CHANG, K.

Structure-Activity Relationships of a Synthetic Pentapeptide that Specifically Releases Growth Hormone in Vitro^*

Tulane Medical School New Orleans, Louisiana 70112;
Memphis State University Memphis, Tennessee 38152;
Beckman Instruments Palo Alto, California 94304

Address requests for reprints to: Dr. C. Y. Bowers, Tulane Medical School, 1430 Tulane Avenue, New Orleans, Louisiana 70112.

Abstract

Tyr-DTrp-Gly-Phe-Met-NH₂ is a unique synthetic Met⁵-enkephalin peptide analog that at concentrations of 1–100 µg/ml incubation medium acts directly on the pituitary of rats in vitro to release GH specifically but not LH, FSH, TSH, PRL, or ACTH. Structure-activity studies of this pentapeptide emphasize the prime importance of an aromatic amino acid residue at the 2 position for in vitro GH-releasing activity. Both Tyr-DTrp-Gly-Phe-Met-NH₂, and Tyr-DPhe-Gly-Phe-Met-NH2 released GH in vitro, while large concentrations of seven enkephalin analogs, which did not have an aromatic amino acid residue in the 2 position, had essentially no GH-releasing activity. In addition, the importance of a DTrp or DPhe rather than an LTrp or LPhe residue in the 2 position was apparent, since neither Tyr-LTrp-Gly-Phe-Met-NH₂ nor Tyr-LPhe-Gly-Phe- Met-NH₂ were active. Although the GH-releasing activity of the C-terminal nonamidated Tyr-DTrp-Gly-Phe-Met peptide was not determined, the nonamidated Tyr-DPhe-Gly-Phe-Met peptide was inactive. Morphine, Met⁵ or Leu⁵ enkephalin peptides, and several of the potent DAla², Met⁵ enkephalin amide opiate active analogs did not have in vitro GH-releasing activity. The opiate antagonist, naloxone, failed to inhibit the release of GH induced by Tyr-DTrp-Gly-Phe-Met-NH₂. Although the GH-releasing pentapeptides described lack the potency of a natural hormone, they may prove valuable for understanding the structure- activity relationships of small peptides that act directly on the pituitary to release GH. From previous experience in synthesizing analogs of the hypothalamic hypophysiotrophic hormones with increased potency, it seems likely that more potent peptides related to Tyr-DTrp-Gly-Phe-Met-NH₂ will be designed. (Endocrinology 106: 663, 1980)

Footnotes

^* This work was supported by NIH Research Grant AM-06164.

Received June 12, 1979.

This article has been cited by other articles:

				T. Chen, Z. Tang, A. Yan, W. Li, and H. Lin Molecular cloning and mRNA expression analysis of two GH secretagogue receptor transcripts in orange-spotted grouper (Epinephelus coioides) J. Endocrinol., November 1, 2008; 199(2): 253 - 265. [Abstract] [Full Text] [PDF]

				D. Stevanovic, V. Milosevic, D. Nesic, V. Ajdzanovic, V. Starcevic, and W. B. Severs A BRIEF COMMUNICATION: Central Effects of Ghrelin on Serum Growth Hormone and Morphology of Pituitary Somatotropes in Rats. Experimental Biology and Medicine, November 1, 2006; 231(10): 1610 - 1615. [Abstract] [Full Text] [PDF]

				N. A. Tritos and E. G. Kokkotou The Physiology and Potential Clinical Applications of Ghrelin, a Novel Peptide Hormone Mayo Clin. Proc., May 1, 2006; 81(5): 653 - 660. [Abstract] [Full Text] [PDF]

				J. V. Zhang, P.-G. Ren, O. Avsian-Kretchmer, C.-W. Luo, R. Rauch, C. Klein, and A. J. W. Hsueh Obestatin, a Peptide Encoded by the Ghrelin Gene, Opposes Ghrelin's Effects on Food Intake Science, November 11, 2005; 310(5750): 996 - 999. [Abstract] [Full Text] [PDF]

				B. Holst, E. Brandt, A. Bach, A. Heding, and T. W. Schwartz Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling Mol. Endocrinol., September 1, 2005; 19(9): 2400 - 2411. [Abstract] [Full Text] [PDF]

				Y. Nishi, H. Hiejima, H. Mifune, T. Sato, K. Kangawa, and M. Kojima Developmental Changes in the Pattern of Ghrelin's Acyl Modification and the Levels of Acyl-Modified Ghrelins in Murine Stomach Endocrinology, June 1, 2005; 146(6): 2709 - 2715. [Abstract] [Full Text] [PDF]

				L. S. Farhy and J. D. Veldhuis Deterministic construct of amplifying actions of ghrelin on pulsatile growth hormone secretion Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1649 - R1663. [Abstract] [Full Text] [PDF]

				M. Kojima and K. Kangawa Ghrelin: Structure and Function Physiol Rev, April 1, 2005; 85(2): 495 - 522. [Abstract] [Full Text] [PDF]

				C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300. [Abstract] [Full Text] [PDF]

				A. INUI, A. ASAKAWA, C. Y. BOWERS, G. MANTOVANI, A. LAVIANO, M. M. MEGUID, and M. FUJIMIYA Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ FASEB J, March 1, 2004; 18(3): 439 - 456. [Abstract] [Full Text] [PDF]

				B. Holst, A. Cygankiewicz, T. H. Jensen, M. Ankersen, and T. W. Schwartz High Constitutive Signaling of the Ghrelin Receptor--Identification of a Potent Inverse Agonist Mol. Endocrinol., November 1, 2003; 17(11): 2201 - 2210. [Abstract] [Full Text] [PDF]

				X.-B. Xu, J.-M. Cao, J.-J. Pang, R.-K. Xu, C. Ni, W.-L. Zhu, K. Asotra, M.-C. Chen, and C. Chen The Positive Inotropic and Calcium-Mobilizing Effects of Growth Hormone-Releasing Peptides on Rat Heart Endocrinology, November 1, 2003; 144(11): 5050 - 5057. [Abstract] [Full Text] [PDF]

				S. R. Cunha and K. E. Mayo Ghrelin and Growth Hormone (GH) Secretagogues Potentiate GH-Releasing Hormone (GHRH)-Induced Cyclic Adenosine 3',5'-Monophosphate Production in Cells Expressing Transfected GHRH and GH Secretagogue Receptors Endocrinology, December 1, 2002; 143(12): 4570 - 4582. [Abstract] [Full Text] [PDF]

				M. Tschop, M. A. Statnick, T. M. Suter, and M. L. Heiman GH-Releasing Peptide-2 Increases Fat Mass in Mice Lacking NPY: Indication for a Crucial Mediating Role of Hypothalamic Agouti-Related Protein Endocrinology, February 1, 2002; 143(2): 558 - 568. [Abstract] [Full Text] [PDF]

				T. L. Horvath, S. Diano, P. Sotonyi, M. Heiman, and M. Tschop Minireview: Ghrelin and the Regulation of Energy Balance--A Hypothalamic Perspective Endocrinology, October 1, 2001; 142(10): 4163 - 4169. [Abstract] [Full Text] [PDF]

				S. M. Anderson, N. Shah, W. S. Evans, J. T. Patrie, C. Y. Bowers, and J. D. Veldhuis Short-Term Estradiol Supplementation Augments Growth Hormone (GH) Secretory Responsiveness to Dose-Varying GH-Releasing Peptide Infusions in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 551 - 560. [Abstract] [Full Text]

				Y. Date, M. Kojima, H. Hosoda, A. Sawaguchi, M. S. Mondal, T. Suganuma, S. Matsukura, K. Kangawa, and M. Nakazato Ghrelin, a Novel Growth Hormone-Releasing Acylated Peptide, Is Synthesized in a Distinct Endocrine Cell Type in the Gastrointestinal Tracts of Rats and Humans Endocrinology, November 1, 2000; 141(11): 4255 - 4261. [Abstract] [Full Text] [PDF]

				N. Shah, W. S. Evans, C. Y. Bowers, and J. D. Veldhuis Oral Estradiol Administration Modulates Continuous Intravenous Growth Hormone (GH)-Releasing Peptide-2-Driven GH Secretion in Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2649 - 2659. [Abstract] [Full Text]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				V. Mericq, F. Cassorla, T. Salazar, A. Avila, G. Iñiguez, C. Y. Bowers, and G. R. Merriam Effects of Eight Months Treatment with Graded Doses of a Growth Hormone (GH)-Releasing Peptide in GH-Deficient Children J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2355 - 2360. [Abstract] [Full Text]

				D. Micic, V. Popovic, M. Doknic, D. Macut, C. Dieguez, and F. F. Casanueva Preserved Growth Hormone (GH) Secretion in Aged and Very Old Subjects after Testing with the Combined Stimulus GH-Releasing Hormone plus GH-Releasing Hexapeptide-6 J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2569 - 2572. [Abstract] [Full Text]

				J. Svensson, L. Lönn, J.-O. Jansson, G. Murphy, D. Wyss, D. Krupa, K. Cerchio, W. Polvino, B. Gertz, I. Boseaus, et al. Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 362 - 369. [Abstract] [Full Text]

				I. Shimon, X. Yan, and S. Melmed Human Fetal Pituitary Expresses Functional Growth Hormone-Releasing Peptide Receptors J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 174 - 178. [Abstract] [Full Text]

				P. A. Bennett, G. B. Thomas, A. D. Howard, S. D. Feighner, L. H. T. Van der Ploeg, R. G. Smith, and I. C. A. F. Robinson Hypothalamic Growth Hormone Secretagogue-Receptor (GHS-R) Expression Is Regulated by Growth Hormone in the Rat Endocrinology, November 1, 1997; 138(11): 4552 - 4557. [Abstract] [Full Text] [PDF]

				H. Hosoda, M. Kojima, H. Matsuo, and K. Kangawa Purification and Characterization of Rat des-Gln14-Ghrelin, a Second Endogenous Ligand for the Growth Hormone Secretagogue Receptor J. Biol. Chem., July 14, 2000; 275(29): 21995 - 22000. [Abstract] [Full Text] [PDF]